These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 31622440)

  • 1. Efficacy of cotrimoxazole (Sulfamethoxazole-Trimethoprim) as a salvage therapy for the treatment of bone and joint infections (BJIs).
    Deconinck L; Dinh A; Nich C; Tritz T; Matt M; Senard O; Bessis S; Bauer T; Rottman M; Salomon J; Bouchand F; Davido B
    PLoS One; 2019; 14(10):e0224106. PubMed ID: 31622440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of trimethoprim-sulfamethoxazole based combination therapy against Stenotrophomonas maltophilia: in vitro effects and clinical efficacy in cancer patients.
    Araoka H; Baba M; Okada C; Abe M; Kimura M; Yoneyama A
    Int J Infect Dis; 2017 May; 58():18-21. PubMed ID: 28257816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trimethoprim/Sulfamethoxazole vs Minocycline for the Treatment of Nonurinary Monomicrobial
    Hevia EC; Wooten L; Carr AL
    Ann Pharmacother; 2024 Jul; 58(7):698-704. PubMed ID: 37776160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sulfamethoxazole/trimethoprim versus fluoroquinolones for the treatment of Stenotrophomonas maltophilia bloodstream infections.
    Watson L; Esterly J; Jensen AO; Postelnick M; Aguirre A; McLaughlin M
    J Glob Antimicrob Resist; 2018 Mar; 12():104-106. PubMed ID: 28964955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of linezolid or trimethoprim/sulfamethoxazole in combination with rifampicin as alternative oral treatments based on an in vitro pharmacodynamic model of staphylococcal biofilm.
    El Haj C; Murillo O; Ribera A; Lloberas N; Gómez-Junyent J; Tubau F; Fontova P; Cabellos C; Ariza J
    Int J Antimicrob Agents; 2018 Jun; 51(6):854-861. PubMed ID: 29374577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monotherapy with fluoroquinolone or trimethoprim-sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections.
    Wang YL; Scipione MR; Dubrovskaya Y; Papadopoulos J
    Antimicrob Agents Chemother; 2014; 58(1):176-82. PubMed ID: 24145530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerance of rifampicin-linezolid compared with rifampicin-cotrimoxazole combinations in prolonged oral therapy for bone and joint infections.
    Nguyen S; Pasquet A; Legout L; Beltrand E; Dubreuil L; Migaud H; Yazdanpanah Y; Senneville E
    Clin Microbiol Infect; 2009 Dec; 15(12):1163-9. PubMed ID: 19438638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparisons between patients with trimethoprim-sulfamethoxazole-susceptible and trimethoprim-sulfamethoxazole-resistant Stenotrophomonas maltophilia monomicrobial bacteremia: A 10-year retrospective study.
    Wang CH; Lin JC; Lin HA; Chang FY; Wang NC; Chiu SK; Lin TY; Yang YS; Kan LP; Yang CH; Chan MC; Yeh KM
    J Microbiol Immunol Infect; 2016 Jun; 49(3):378-86. PubMed ID: 25081988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monomicrobial bone and joint infection due to Corynebacterium striatum: literature review and amoxicillin-rifampin combination as treatment perspective.
    Noussair L; Salomon E; El Sayed F; Duran C; Bouchand F; Roux AL; Gaillard JL; Bauer T; Rottman M; Dinh A
    Eur J Clin Microbiol Infect Dis; 2019 Jul; 38(7):1269-1278. PubMed ID: 30903537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral antibiotics for the treatment of Gram-negative bloodstream infections: A retrospective comparison of three antibiotic classes.
    Nisly SA; McClain DL; Fillius AG; Davis KA
    J Glob Antimicrob Resist; 2020 Mar; 20():74-77. PubMed ID: 31390537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ambulatory treatment of multidrug-resistant Staphylococcus-infected orthopedic implants with high-dose oral co-trimoxazole (trimethoprim-sulfamethoxazole).
    Stein A; Bataille JF; Drancourt M; Curvale G; Argenson JN; Groulier P; Raoult D
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3086-91. PubMed ID: 9835495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors and molecular mechanisms associated with trimethoprim-sulfamethoxazole resistance in Stenotrophomonas maltophilia in Mexico.
    Herrera-Heredia SA; Pezina-Cantú C; Garza-González E; Bocanegra-Ibarias P; Mendoza-Olazarán S; Morfín-Otero R; Camacho-Ortiz A; Villarreal-Treviño L; Rodríguez-Noriega E; Paláu-Davila L; Maldonado-Garza HJ; Flores-Treviño S
    J Med Microbiol; 2017 Aug; 66(8):1102-1109. PubMed ID: 28771141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluoroquinolones versus trimethoprim-sulfamethoxazole for the treatment of Stenotrophomonas maltophilia infections: a systematic review and meta-analysis.
    Ko JH; Kang CI; Cornejo-Juárez P; Yeh KM; Wang CH; Cho SY; Gözel MG; Kim SH; Hsueh PR; Sekiya N; Matsumura Y; Lee DG; Cho SY; Shiratori S; Kim YJ; Chung DR; Peck KR
    Clin Microbiol Infect; 2019 May; 25(5):546-554. PubMed ID: 30448331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Fluoroquinolones or Sulfamethoxazole-Trimethoprim Compared to Β-Lactams for Oral Step-Down Therapy in Hospitalized Patients With Uncomplicated Enterobacterales Bacteremia.
    Mack T; Hiles JJ; Wrin J; Desai A
    Ann Pharmacother; 2023 Mar; 57(3):251-258. PubMed ID: 35758168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pristinamycin in the treatment of MSSA bone and joint infection.
    Valour F; Boibieux A; Karsenty J; Vallat MP; Braun E; Perpoint T; Biron F; Laurent F; Lustig S; Chidiac C; Ferry T;
    J Antimicrob Chemother; 2016 Apr; 71(4):1063-70. PubMed ID: 26801082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage therapy for complex bone and joint infections with ceftaroline: a multicentre, observational study.
    Malandain D; Dinh A; Ferry T; Touchais S; Lustig S; Laurent F; Corvec S; Bémer P; Asseray N; Boutoille D
    Int J Antimicrob Agents; 2017 Aug; 50(2):277-280. PubMed ID: 28689872
    [No Abstract]   [Full Text] [Related]  

  • 17. Teicoplanin-based antimicrobial therapy in Staphylococcus aureus bone and joint infection: tolerance, efficacy and experience with subcutaneous administration.
    Peeters O; Ferry T; Ader F; Boibieux A; Braun E; Bouaziz A; Karsenty J; Forestier E; Laurent F; Lustig S; Chidiac C; Valour F;
    BMC Infect Dis; 2016 Nov; 16(1):622. PubMed ID: 27809799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Old antimicrobials and Gram-positive cocci through the example of infective endocarditis and bone and joint infections.
    Seng P; Amrane S; Million M; Stein A
    Int J Antimicrob Agents; 2017 May; 49(5):558-564. PubMed ID: 28365430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fusidic acid for the treatment of bone and joint infections caused by meticillin-resistant Staphylococcus aureus.
    Wang JL; Tang HJ; Hsieh PH; Chiu FY; Chen YH; Chang MC; Huang CT; Liu CP; Lau YJ; Hwang KP; Ko WC; Wang CT; Liu CY; Liu CL; Hsueh PR
    Int J Antimicrob Agents; 2012 Aug; 40(2):103-7. PubMed ID: 22612900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta-lactams in continuous infusion for Gram-negative bacilli osteoarticular infections: an easy method for clinical use.
    Ribera A; Soldevila L; Rigo-Bonnin R; Tubau F; Padullés A; Gómez-Junyent J; Ariza J; Murillo O
    Infection; 2018 Apr; 46(2):239-244. PubMed ID: 29363049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.